<\/b><\/p>\n
<\/b><\/p>\n
MONDAY, Jan. 27, 2020 (HealthDay News) — In an American Society of Clinical Oncology\/College of American Pathologists updated guideline, published online Jan. 13 in the Archives of Pathology & Laboratory Medicine<\/i> and the Journal of Clinical Oncology<\/i>, recommendations are presented for estrogen and progesterone receptor (ER\/PgR) testing in breast cancer.<\/p>\n
Kimberly H. Allison, M.D., from the Stanford University School of Medicine in California, and colleagues convened a multidisciplinary international expert panel to update the clinical practice guideline recommendations for ER and PgR testing in breast cancer.<\/p>\n
The expert panel continues to recommend validated immunohistochemistry for ER testing of invasive breast cancers as the standard for predicting benefit from endocrine therapy. Samples with 1 to 100 percent of tumor nuclei positive should be considered ER-positive. However, limited data are available on the benefit of endocrine therapy for cancers with 1 to 10 percent of cells staining ER-positive, now described in a new reporting category called ER-low positive. A sample with <1 or 0 percent of tumor cell nuclei immunoreactive should be considered ER-negative. To promote optimal performance, interpretation, and reporting of cases with an initial low to no ER staining result, additional strategies include establishing a laboratory specific standard operating procedure describing additional steps used to confirm\/adjudicate results. PgR testing continues to be used primarily to help determine prognosis in ER-positive breast cancers. Testing ductal carcinoma in situ for ER is recommended while testing for PgR is considered optional.<\/p>\n
“The critical point for clinicians is that they need to be aware of and able to discuss with patients the implications of ER-low positive test results,” a coauthor said in a statement.<\/p>\n
Several authors disclosed financial ties to the pharmaceutical and biotechnology industries.<\/p>\n
Abstract\/Full Text – Archives of Pathology & Laboratory Medicine<\/i><\/a><\/p>\n Abstract\/Full Text – Journal of Clinical Oncology<\/i><\/a><\/p>\n <\/i><\/p>\n